Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

[Relationship between red blood cell transfusion volume and posttransfusional iron overload in hematological diseases].

Ashida T, Kawano A, Yamada E, Ide D, Sugano C, Kato Y, Tsubakimoto Y, Ito S, Mine Y, Fujita M, Kanemitsu Y, Morishima Y, Morita Y, Tanaka H, Shimada T, Kawanishi K, Miyatake J, Tatsumi Y, Matsumura I.

Rinsho Ketsueki. 2013 Apr;54(4):365-9. Japanese.

PMID:
23666218
2.

Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.

Kim IH, Moon JH, Lim SN, Sohn SK, Kim HG, Lee GW, Kim YS, Lee HS, Kwon KY, Kim SH, Park KT, Chung JS, Lee WS, Lee SM, Hyun MS, Kim H, Ryoo HM, Bae SH, Joo YD.

Transfusion. 2015 Jul;55(7):1613-20. doi: 10.1111/trf.13036. Epub 2015 Mar 11.

PMID:
25764017
3.

Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.

Cheong JW, Kim HJ, Lee KH, Yoon SS, Lee JH, Park HS, Kim HY, Shim H, Seong CM, Kim CS, Chung J, Hyun MS, Jo DY, Jung CW, Sohn SK, Yoon HJ, Kim BS, Joo YD, Park CY, Min YH; Korean Society of Hematology Acute Myeloid Leukemia/Myelodysplastic Syndrome Working Party.

Transfusion. 2014 Jun;54(6):1542-51. doi: 10.1111/trf.12507. Epub 2013 Dec 3.

PMID:
24313463
4.

Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.

Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.

Ann Hematol. 2011 Jun;90(6):655-66. doi: 10.1007/s00277-011-1164-9. Epub 2011 Feb 12.

PMID:
21318574
5.

Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.

Malcovati L.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S305-11. doi: 10.3816/CLM.2009.s.029. Review.

PMID:
19778858
6.

[The role of iron metabolism in myelodysplastic syndromes].

Finelli C, Clissa C, Stanzani M.

Recenti Prog Med. 2014 Mar;105(3):123-6. doi: 10.1701/1434.15874. Italian.

PMID:
24675455
7.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
8.

Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.

Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, Nakao S, Nakahata T, Harada M, Murate T, Ozawa K; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes.

Eur J Haematol. 2007 Jun;78(6):487-94. Epub 2007 Mar 28.

PMID:
17391310
9.

Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.

Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW.

Acta Haematol. 2013;129(2):72-7. doi: 10.1159/000342772. Epub 2012 Nov 15.

PMID:
23154600
10.

[Iron overload and myelodysplastic syndromes].

Rose C, Cambier N, Mahieu M, Ernst O, Fenaux P.

Transfus Clin Biol. 2001 Oct;8(5):422-32. Review. French.

PMID:
11729396
11.

Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.

Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.

Ann Hematol. 2010 Feb;89(2):147-54. doi: 10.1007/s00277-009-0794-7. Epub 2009 Aug 19.

PMID:
19690857
12.

Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.

Jabbour E, Kantarjian HM, Koller C, Taher A.

Cancer. 2008 Mar 1;112(5):1089-95. doi: 10.1002/cncr.23280. Review.

13.

Estimation of cardiac left ventricular ejection fraction in transfusional cardiac iron overload by R2* magnetic resonance.

Sakuta J, Ito Y, Kimura Y, Park J, Tokuuye K, Ohyashiki K.

Int J Hematol. 2010 Dec;92(5):708-12. doi: 10.1007/s12185-010-0719-1. Epub 2010 Nov 25.

PMID:
21107770
14.

Clinical characteristics and management of iron overload in 631 patients with chronic transfusion dependency: results from a multicentre, observational study.

Cid J, Palomera L, Díaz M, Zamora C, Solano F.

Blood Transfus. 2014 Jan;12 Suppl 1:s119-23. doi: 10.2450/2013.0173-12. Epub 2013 Mar 14.

15.

Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.

Alessandrino EP, Della Porta MG, Bacigalupo A, Malcovati L, Angelucci E, Van Lint MT, Falda M, Onida F, Bernardi M, Guidi S, Lucarelli B, Rambaldi A, Cerretti R, Marenco P, Pioltelli P, Pascutto C, Oneto R, Pirolini L, Fanin R, Bosi A.

Haematologica. 2010 Mar;95(3):476-84. doi: 10.3324/haematol.2009.011429. Epub 2009 Nov 10.

16.

Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.

Remacha ÁF, Arrizabalaga B, Villegas A, Durán MS, Hermosín L, de Paz R, Garcia M, Diez Campelo M, Sanz G; IRON-2 Study Group.

Ann Hematol. 2015 May;94(5):779-87. doi: 10.1007/s00277-014-2274-y. Epub 2014 Dec 18.

PMID:
25516455
17.

Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients.

Hilliard LM, Williams BF, Lounsbury AE, Howard TH.

Am J Hematol. 1998 Sep;59(1):28-35.

18.

Korean guideline for iron chelation therapy in transfusion-induced iron overload.

Jang JH, Lee JH, Yoon SS, Jo DY, Kim HJ, Chung J, Lee JW; Korean Society of Hematology Aplastic Anemia Working Party.

J Korean Med Sci. 2013 Nov;28(11):1563-72. doi: 10.3346/jkms.2013.28.11.1563. Epub 2013 Oct 31.

19.

Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.

Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, Takada K, Ono K, Kaneko Y, Miyanishi K, Sato Y, Hayashi T, Takimoto R, Kato J.

Free Radic Biol Med. 2012 Aug 15;53(4):643-8. doi: 10.1016/j.freeradbiomed.2012.06.006. Epub 2012 Jun 15.

PMID:
22705364
20.

Effectiveness of red blood cell exchange, partial manual exchange, and simple transfusion concurrently with iron chelation therapy in reducing iron overload in chronically transfused sickle cell anemia patients.

Fasano RM, Leong T, Kaushal M, Sagiv E, Luban NL, Meier ER.

Transfusion. 2016 Jul;56(7):1707-15. doi: 10.1111/trf.13558. Epub 2016 Mar 20.

PMID:
26997031

Supplemental Content

Support Center